Subjects and methods
Subjects. The Rotterdam Study is a population-based prospective follow-up study in which several important diseases of the elderly are investigated [16] . The study focuses on four groups of diseases: neurological, cardiovascular, locomotor and ophthalmologic. All inhabitants of Ommoord, a suburb of Rotterdam, aged 55 years and older, including those living in institutions, were invited to participate in the study. Of the 10 275 eligible subjects, 7983 participated in the Rotterdam Study. Between 1990 and 1993 participants were extensively interviewed at their homes and examined at the research centre in order to collect baseline data and to ascertain their health status. Dementia status was missing in 455 (6 %) subjects, mainly because they refused the cognitive screening test. Blood glucose measurements started in July 1990, after the pilot phase in which 544 randomly choosen participants were examined. Of the 7439 subjects who were examined since then, blood glucose measurements were absent in 821 (11 %), mainly due to logistic or technical problems. In the present analyses 6330 participants (85 %), with complete information on drug use, blood glucose measurements and the presence of dementia were included. Dementia and diabetes assessments took place completely independent of each other without prior knowledge of the study physicians about which associations would later be tested.
Examinations. The prevalence of dementia was assessed using a three-phase approach [17] . With a brief cognitive test, the combined Mini Mental State Examination (MMSE) [18] and Geriatric Mental State schedule (GMS-A, organic level) [19] , the population was screened for dementia. This test was administered by trained research assistants. Screen positive subjects (Mini Mental State Examination score below 26 or Geriatric Mental State score above 0) were subsequently examined by a physician with the Cambridge Examination for Mental Disorders of the Elderly diagnostic interview [20] . Participants who were suspected of dementia after this interview underwent an extensive examination which included examinations by a neurologist, a neuropsychologist and brain magnetic resonance imaging. Based on all available information a diagnosis of dementia was then made according to Diagnostic and Statistical Manual of mental disorders criteria [21] , with a subdiagnosis of AD based on National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer's Disease and Related Disorders Association criteria [22] and of vascular dementia in accordance with National Institute of Neurological Disorders and Stroke and Association Internationale pour la Recherche et l'Enseignement en Neurosciences criteria [23] .
Current drug use was assessed during the initial home interview. Participants were asked to show all medication they were using. Of institutionalised participants, medication was reported by the medical staff. From all participants blood was drawn by venipuncture and allowed to coagulate for 30 min. Subjects without anti-diabetic medication subsequently received a 200 ml glucose drink which contained 75 g of glucose; a second blood sample was obtained 2 h later. Random and post-load glucose levels were measured by the glucose hexokinase method. Diabetes was defined as the use of anti-diabetic medication or at least one glucose value greater than 11 mmol/l.
Level of education was assessed during the initial interview and grouped in four levels, from primary school only, to college and higher. Smoking habits were assessed during interview and categorised as never, former or current smoking. Body mass index was calculated by dividing weight through the square of height and expressed as kg/m 2 . Systolic blood pressure was measured with a random zero sphygmomanometer. The ankle-to-brachial index (the ratio of the systolic blood pressure measured at the ankle and the upper arm) was used as a measure of peripheral atherosclerosis: a ratio of 0.9 or below was considered positive [24] . Resting ECGs were analysed by the Modular ECG Analysis System (MEANS) computer program [25] . This program contains modules for rhythm classification, contour analyses and Minnesota coding and was shown to give very accurate ECG diagnoses [26] . The presence of coronary artery disease, was approximated by the program's diagnosis of probable or definite myocardial infarction, which was used as a second measure of atherosclerosis. A history of stroke was determined through interview or in dementia patients through informant interview, and verified with medical records.
Statistical analysis
The association between NIDDM and dementia was examined by calculating odds ratios (OR) by multivariate logistic regression with dementia as the dependent, and NIDDM, age and sex as independent variables in the model. In all regression models age was treated as a continuous variable. To assess whether this relation was different across levels of severity of NIDDM, we performed subanalyses in which we compared patients without anti-diabetes medication, patients using oral anti-diabetes medication and patients treated with insulin, to non-diabetic subjects. In addition to age and sex, we included educational level, smoking, body mass index, atherosclerosis, systolic blood pressure level and antihypertensive drug treatment to the regression model in order to adjust for confounding by these variables. To examine whether the association could be explained by an increased stroke risk in diabetic patients, the analyses were repeated in subjects without stroke history.
Results
Of the 6330 subjects in this study, 265 (4.2 %) were diagnosed with dementia (Table 1) . In 194 the dementia was of the Alzheimer's disease (AD) type (73 %), 44 subjects had a vascular dementia (17 %), and 27 had other dementias (10 %). Of the AD patients 32 (16 %) had cerebrovascular disease, based on a history of stroke or cerebral magnetic resonance imaging findings, that was considered not directly aetiologically related to the dementia. Ages ranged from 55 to 99 years. Dementia prevalence increased sharply with age: from 0.3 % in the age group 55-64 years to 30 % in subjects of 85 and older. Since the older age groups had higher proportions of women, there were relatively more women with dementia. The prevalence of NIDDM also increased with age: from 6 % in the age group of 55-64 years to 22 % in subjects of 85 and older. NIDDM was diagnosed in 11 % of the non-demented participants and in 22 % of the dementia patients. Among AD, vascular and other dementia patients, 21, 30 and 19 % had NIDDM, respectively. Of the NIDDM patients 34 % were using oral medication and 10 % received insulin treatment. These proportions were similar among the dementia patients. After adjustment for age and sex differences, dementia patients had a significantly higher serum glucose level, a lower body mass index and systolic blood pressure, more frequent history of stroke and a lower educational status than subjects without dementia. Table 2 shows the association between diabetes and dementia for the total population and for men and women separately. In women a significant association with dementia was observed (OR: 1.5, 95 % confidence interval (CI) 1.0-2.2). However, NIDDM treated with insulin was strongly correlated to dementia in both men and women (OR: 3.2, 95 % CI: 1.4-7.5, for both sexes combined). Additional adjustments for possible confounders only marginally altered the associations.
Both NIDDM and dementia patients more often had stroke histories than participants without diabetes or dementia. Excluding subjects with a history of stroke however, did not change the association between diabetes and dementia (OR: 1.3, 95 % CI: 0.9-1.9 for overall NIDDM and OR: 3.0, 95 % CI: 1.1-7.8 for NIDDM treated with insulin).
In Table 3 the associations between diabetes and dementia subtypes are given. The association of insulin-treated NIDDM to dementia was observed for all subtypes, but was strongest for vascular dementia. Diabetes treated with oral medication was significantly associated with vascular dementia. Again additional adjustments for confounders resulted in essentially similar associations.
Discussion
In this study we investigated the relation between NIDDM and dementia. NIDDM treated with insulin was strongly associated with dementia and this was independent of level of education, smoking, body mass index, presence of atherosclerosis, systolic blood pressure and antihypertensive medication. The association could not be explained by an increased prevalence of clinical strokes. The association was found with vascular dementia and Alzheimer's disease (AD). In vascular dementia the relation tended to be stronger with more severe NIDDM, whereas in AD an association was mainly found with NIDDM treated with insulin. Three possible biases need to be discussed. Firstly, we did not obtain a 100 % response. We do know that non-responders were on average older than the study participants. Dementia patients more often had to be excluded due to incomplete diabetes information. This, however, would only invalidate our results if the relation between NIDDM and dementia was different among non-responders as compared to participants, which we consider unlikely. Secondly, because we studied the relation between diabetes and dementia cross-sectionally, bias could have occurred due to survival effects [27] . This could have resulted in an overestimation of the relation if the relative decrease in survival due to diabetes would be greater in non-demented than demented subjects or in an underestimation if the combination of NIDDM and dementia in a patient would interact and lead to increased mortality. If anything, we consider the latter more likely. Thirdly, subtyping dementia, even if based on generally accepted diagnostic criteria, remains difficult and some misclassification cannot be excluded. Furthermore, although the criteria for vascular dementia are appropriate for identifying multiinfarct dementia, they may fail to identify subjects in whom other vascular mechanisms played an important aetiological role, and vascular factors may also be involved in AD [11, 23, 28, 29] . In the present study AD was associated with NIDDM, particularly when treated with insulin, even after exclusion of patients with cerebrovascular disease from the AD group.
The relation of NIDDM with dementia was similar between men and women only for NIDDM treated with insulin. In untreated and tablet-treated NIDDM a relation with dementia also seemed present in women but not in men. We do not know if this is simply due to the low number of men with both NIDDM and dementia, resulting in an unstable odds ratio with wide confidence intervals or whether this reflects a greater inpact of NIDDM on women. The latter was suggested in a report from the Framingham Heart Study, in which relatively more cardiovascular disease was found in diabetic women than men [30] .
Our results indicated that atherosclerosis had only limited influence on the association between NIDDM and dementia. However, we cannot completely exclude atherosclerosis as an aetiologic factor. In order to investigate the relative contribution of strokes we investigated the association in a subgroup without history of stroke. Though the association was also found in subjects without a history of stroke it remains possible that silent infarctions due to NIDDM pathology may underlie the excess of dementia in diabetic subjects.
Our finding of an increased prevalence of vascular dementia in diabetic patients is in line with results from a study in which 175 multi-infarct dementia patients were compared with 125 age-matched neurologically normal control subjects [31] . Diabetes was 2.8 times more prevalent in cases than in control subjects. In a recent Japanese community-based study on the incidence of dementia, it was shown that NIDDM patients had an increased risk of developing vascular dementia (age adjusted relative risk: 2.8) [15] . Furthermore, Tatemichi et al. [32] showed that in stroke patients, diabetes was associated with a higher rate of dementia 3 months after the stroke (OR: 2.6).
Our findings of a relation between insulin-treated NIDDM and AD contrasts with results of studies which suggested that diabetes is less frequent among AD patients than control subjects [12] [13] [14] . These studies were relatively small, used selected clinical AD cases, and geriatric clinic patients [12] , vascular dementia [13] or population control subjects [14] . Our results are in accordance with the Japanese Hisayama Study which reported that NIDDM patients had an increased risk of developing AD after 7 years of follow-up (relative risk: 2.2, 95 % CI: 1.0-4.9) [15] .
The relation between NIDDM and AD may be explained by diabetic vasculopathy and its sequelae. The common coincidence of AD with cerebral infarctions and subcortical white matter lesions [11, 33, 34] suggests that vascular factors may be important in AD. However, other and more direct mechanisms could be involved. Recently, increased glycation of proteins and advanced glycation end products (AGE), which may be involved in the aetiology of diabetic complications, were found in plaques and tangles of AD patients [35, 36] . AGE epitopes were even detected in the earliest states of Alzheimer brain lesions and do promote known plaque and tangle properties. Progressive glycation augments the deposition of proteins by crosslinking, it induces macrophages to secrete acute-phase reactants, thereby stimulating immune-cell response and it might contribute to nerve-cell death by the formation of free radicals [37, 38] . Alternatively, NIDDM effects on neurotransmitter metabolism could contribute to AD. In chronic diabetes, a considerable decline in the blood-brain barrier transport of choline, a precursor of acetylcholine, has been found [3] . Changes in brain glucose utilisation or insulin-induced hypoglycaemic episodes might contribute to a reduced acetylcholine synthesis [5, 39] . Blocking of acetylcholine muscarinic receptors is known to disrupt higher cognitive functions and AD severity is correlated to the loss of brain cholinergic activity [38, 39] . Finally, we found that the correlation between NIDDM and AD was strongest in NIDDM patients treated with insulin. Most likely these patients had a more serious and long-standing diabetes. It is however conceivable that exogenous insulin itself or hypoglycaemic episodes which frequently complicate insulin therapy [40] increase the risk of dementia and AD. A direct correlation has been reported between increased endogenous insulin level and impaired cognitive function [41] .
In conclusion, we found that NIDDM, particularly when treated with insulin, is associated with dementia, both vascular dementia and AD. It is as yet unclear which pathophysiologic mechanisms could explain this association.
